Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting interventional studies whose public record uses ctDNA or MRD to guide treatment, or lists it as a primary endpoint. 110 studies from 454 registry hits. Last synced Nov 14, 2026, 9:51 PM EST.
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals · 53 locations · Updated 2026-11-04
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center · 1 locations · Updated 2026-11-02
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Michael Spinner, MD · 6 locations · Updated 2026-10-20
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine · 1 locations · Updated 2026-08-06
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2026-06-26
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
SCRI Development Innovations, LLC · 11 locations · Updated 2026-06-04
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
The First Affiliated Hospital of Soochow University · 2 locations · Updated 2026-03-20
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2026-02-04
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Hua-Jay J Cherng, MD · 1 locations · Updated 2026-01-23
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Danielle Wallace · 1 locations · Updated 2025-10-20
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Zhujiang Hospital · 1 locations · Updated 2025-03-30
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Oslo University Hospital · 13 locations · Updated 2025-03-20
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
PETHEMA Foundation · 1 locations · Updated 2024-10-26
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2023-12-06
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Paolo Ghia · 1 locations · Updated 2023-10-04
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-10-27
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
University of Washington · 6 locations · Updated 2026-09-09
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
M.D. Anderson Cancer Center · 1 locations · Updated 2026-08-10
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
Yale University · 1 locations · Updated 2026-06-22
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Rong Tao · 1 locations · Updated 2026-06-18
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Jennifer Amengual · 2 locations · Updated 2026-05-27
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
University Health Network, Toronto · 3 locations · Updated 2026-04-24
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.